{"componentChunkName":"component---node-modules-gatsby-theme-buzzing-src-gatsby-theme-blog-core-templates-post-query-js","path":"/zh-Hant/reddit/r/stocks/comments/q21jy9/jspr_stem_cell_bio_with_major_buyin_from_amgn/","result":{"data":{"site":{"siteMetadata":{"title":"国外股市热门","author":"Buzzing.cc","description":"用中文浏览国外股票社区里的热门讨论","keywords":["buzzing","美股","股票","股市"],"siteUrl":"https://stocks.buzzing.cc","telegram":"@stocks_top","iconUrl":"https://stocks.buzzing.cc/avatar.png","defaultSocialImageUrl":null,"social":[{"name":"Reddit Stocks","url":"https://www.reddit.com/r/stocks","external":true},{"name":"Reddit Investing","url":"https://www.reddit.com/r/investing","external":true},{"name":"Charlie Bilello's twitter","url":"https://twitter.com/charliebilello","external":true},{"name":"Buzzing","url":"https://www.buzzing.cc/","external":true}],"menuLinks":[{"name":"每周精选","url":"/issues","external":null}],"disqus":null,"utterances":null,"localize":[{"title":"Buzzing on Stocks","description":"See popular discussions in foreign stock communities in your native language","keywords":["buzzing","stocks","U.S. stocks"],"locale":"en","social":{"name":null,"url":null,"external":null},"menuLinks":[{"name":"Weekly Selection","url":"/en/issues","external":null}]},{"title":"國外股市熱門","description":"用中文瀏覽國外股票社區裡的熱門討論","keywords":["buzzing","美股","股票","股市"],"locale":"zh-Hant","social":null,"menuLinks":[{"name":"每週精選","url":"/zh-Hant/issues","external":null}]},{"title":"米国株式市場人気の話し合います","description":"人気の米国株式市場の話し合いまを日本語で閲覧","keywords":["buzzing","米国株式市場"],"locale":"ja","social":null,"menuLinks":[]}]}},"blogPost":{"id":"RedditPost-q21jy9","excerpt":"Jasper Therapeutics has a promising platform for more effective stem cell\ntransplants and cell therapies. The pipeline is extensive and has a number of\nnotable collaborators (see slide). By their own estimates more effective\ntransplant would expand the market from it’s current ~4b size to ~20b…","body":"<!-- SC_OFF --><div class=\"md\"><p>Jasper Therapeutics has a promising platform for more effective stem cell transplants and cell therapies. The pipeline is extensive and has a number of notable collaborators (see slide). By their own estimates more effective transplant would expand the market from it’s current ~4b size to ~20b (see slide). The company has an EV of roughly ~250m at this point. For a company of that size, with the potential to unluck another 16b of market cap – the possibility to be a major multi-bagger is evident.</p>\n\n<p>So what are the catalysts? </p>\n\n<p>(a) Amgen (AMGN, 120B market cap) recently disclosed a major stake (7% of the company), so clearly they see some major potential here.</p>\n\n<p><a href=\"https://www.sec.gov/Archives/edgar/data/318154/000119312521289912/d79598dsc13g.htm\">https://www.sec.gov/Archives/edgar/data/318154/000119312521289912/d79598dsc13g.htm</a></p>\n\n<p>(b) There is a number of catalysts (see slide) that should occur before year</p>\n\n<p>(c) The float seems to be exceptionally tight. Perhaps it only ~700k-4m at this point. The stock has been trading oddly and seem a number of halts on practically no volume.</p>\n\n<p>My thesis is that as more serious traders re-evaluate the company in light of the AMGM position and PR’s are released as they check of these milestones – given the tight float it could run rather hard. </p>\n\n<p>Referenced slides are here</p>\n\n<p><a href=\"https://www.sec.gov/Archives/edgar/data/1788028/000121390021025120/ea140508ex99-2_amplitude.htm\">https://www.sec.gov/Archives/edgar/data/1788028/000121390021025120/ea140508ex99-2_amplitude.htm</a></p>\n</div><!-- SC_ON -->","slug":"/reddit/r/stocks/comments/q21jy9/jspr_stem_cell_bio_with_major_buyin_from_amgn/","title":"JSPR - stem cell bio with major buy-in from AMGN","tags":["stocks","reddit"],"date":"October 06, 2021","dateISO":"2021-10-06T02:43:46.000Z","datetime":"2021-10-06 02:43","image":null,"imageAlt":null,"socialImage":null,"__typename":"SocialMediaPost","thirdPartyId":"q21jy9","provider":"Reddit","url":"https://www.reddit.com/r/stocks/comments/q21jy9/jspr_stem_cell_bio_with_major_buyin_from_amgn/","originalUrl":"https://www.reddit.com/r/stocks/comments/q21jy9/jspr_stem_cell_bio_with_major_buyin_from_amgn/","imageRemote":null,"video":null,"channel":"stocks","channelUrl":"https://www.reddit.com/r/stocks","author":"joeskunk","authorUrl":"https://www.reddit.com/user/joeskunk","authorImage":null,"authorImageRemote":null,"authorSlug":"joeskunk","score":149,"views":null,"sharedCount":null,"likeCount":null,"sharedContent":null,"parent":{"localize":[{"title":"JSPR - AMGNが買収した幹細胞バイオ企業","the_new_excerpt":"ジャスパー・セラピューティック社は、より効果的な幹細胞移植のための有望なプラットフォームを持っています。\nより効果的な幹細胞移植と細胞治療のための有望なプラットフォームを持っています。パイプラインは充実しており、注目すべき共同研究者も多数います。\n注目すべき共同研究者がいます（スライド参照）。彼らの推計によると、より効果的な\n移植がより効果的になれば、市場規模は現在の約40億円から約200億円に拡大します。","locale":"ja"},{"title":"JSPR--干细胞生物，得到AMGN的重大收购。","the_new_excerpt":"Jasper Therapeutics为更有效的干细胞移植和细胞治疗提供了一个很有前景的平台。\n移植和细胞治疗。该公司的管线非常广泛，并有许多著名的合作者。\n显著的合作者（见幻灯片）。根据他们自己的估计,更有效的\n移植将使市场从目前约40亿规模扩大到约200亿。","locale":"zh"},{"title":"JSPR--幹細胞生物，得到AMGN的重大收購。","the_new_excerpt":"Jasper Therapeutics爲更有效的幹細胞移植和細胞治療提供了一個很有前景的平臺。\n移植和細胞治療。該公司的管線非常廣泛，並有許多著名的合作者。\n顯著的合作者（見幻燈片）。根據他們自己的估計,更有效的\n移植將使市場從目前約40億規模擴大到約200億。","locale":"zh-Hant"}]}},"previous":{"id":"RedditPost-q29xn2","excerpt":"Palantir Technologies Inc. shares rallied in the extended session Tuesday after\nthe data-software company said it was selected for a U.S. Army intelligence\nprogram contract.\n\nPalantir PLTR, +0.17% shares surged and were last up 14% after hours, following\na 0.2% rise to close at $23.21.\n\nThe company…","slug":"/reddit/r/investing/comments/q29xn2/palantir_stock_rallies_more_than_10_on_823/","title":"Palantir stock rallies more than 10% on $823 million Army contract","date":"October 06, 2021","__typename":"SocialMediaPost","provider":"Reddit","parent":{"localize":[{"title":"Palantir社の株価は、8億2300万ドルの陸軍契約により10％以上上昇しました。","the_new_excerpt":"Palantir Technologies Inc.の株価は、火曜日の延長セッションで上昇しました。\nデータ・ソフトウェア企業であるPalantir Technologies Inc.の株価は、米国陸軍の情報プログラムの契約に選ばれたと発表した後、延長セッションで上昇しました。\n契約に選ばれました。\n\nPalantir PLTR, +0.17% の株価は急上昇し、時間外に14%の上昇を記録しました。\n23.21ドルで取引を終了しました。\n\n同社は...","locale":"ja"},{"title":"帕兰蒂尔公司股票因8.23亿美元的陆军合同而回升超过10%。","the_new_excerpt":"Palantir Technologies Inc.的股价在周二延长的交易时段中上涨，此前该数据软件公司表示\n这家数据软件公司说它被选中参加美国陆军的情报项目。\n项目合同。\n\nPalantir PLTR, +0.17%股价大涨，盘后最后上涨14%，此前\n上涨0.2%，收于23.21美元。\n\n该公司...","locale":"zh"},{"title":"帕蘭蒂爾公司股票因8.23億美元的陸軍合同而回升超過10%。","the_new_excerpt":"Palantir Technologies Inc.的股價在週二延長的交易時段中上漲，此前該數據軟件公司表示\n這家數據軟件公司說它被選中參加美國陸軍的情報項目。\n項目合同。\n\nPalantir PLTR, +0.17%股價大漲，盤後最後上漲14%，此前\n上漲0.2%，收於23.21美元。\n\n該公司...","locale":"zh-Hant"}]}},"next":{"id":"TweetPost-1445551757094883331","excerpt":"","slug":"/tweet/1445551757094883331","title":"The U.S. government is secretly ordering Google to provide data on anyone typing in certain search terms, an accidentally unsealed court document shows $GOOGL","__typename":"SocialMediaPost","date":"October 06, 2021","provider":"Twitter","parent":{"localize":[{"locale":"ja","full_text":"米国政府は、特定の検索語を入力した人のデータを提供するよう、Google社に密かに命令していることが、誤って公開された裁判所の文書で明らかになった$GOOGL","quoted_status_full_text":null,"retweeted_status_full_text":null},{"locale":"zh","full_text":"美国政府正在秘密命令谷歌提供任何输入某些搜索词的人的数据，一份意外解封的法庭文件显示，$GOOGL","quoted_status_full_text":null,"retweeted_status_full_text":null},{"locale":"zh-Hant","full_text":"美國政府正在祕密命令谷歌提供任何輸入某些搜索詞的人的數據，一份意外解封的法庭文件顯示，$GOOGL","quoted_status_full_text":null,"retweeted_status_full_text":null}]}}},"pageContext":{"basePath":"/","pageType":"detail","id":"RedditPost-q21jy9","previousId":"RedditPost-q29xn2","nextId":"TweetPost-1445551757094883331","maxWidth":1024,"siteMetadata":null,"locale":"zh-Hant","hrefLang":"zh-Hant","originalPath":"/reddit/r/stocks/comments/q21jy9/jspr_stem_cell_bio_with_major_buyin_from_amgn/","dateFormat":"YYYY-MM-DD"}},"staticQueryHashes":["1239077767","2744905544","3280999885"]}